Stage | Target gene | Method | Nsnp | Beta | Pval | Q | Ple | R2 | F | Drugs and Pharmacological action |
---|---|---|---|---|---|---|---|---|---|---|
Discovery | ETFDH | Inverse variance weighted (fixed effects) | 7 | 0.019 | 0.0091 | 0.24 | 0.61 | 0.68 | 19.10 | Metformin (Yes inhibitor) |
Replication | ETFDH | Inverse variance weighted (fixed effects) Weighted median | 5 5 | 0.130 0.095 | 0.0001 0.0360 | 0.55 | 0.33 | 0.23 | 12.20 | |
Discovery | CYP21A2 | Inverse variance weighted | 2 | 0.029 | 0.0166 | NA | NA | 0.19 | 20.17 | Levoketoconazole (No) |
Replication | CYP21A2 | Inverse variance weighted (fixed effects) | 5 | 0.055 | 0.0451 | 0.07 | 0.24 | 0.24 | 25.92 | |
Discovery | CYP2D6 | Inverse variance weighted (fixed effects) Weighted median | 4 4 | -0.017 -0.019 | 0.0253 0.0324 | 0.78 | 0.56 | 0.54 | 27.60 | Dapagliflozin (No) Phenformin (Unkonw) |
Replication | CYP2D6 | Inverse variance weighted (fixed effects) | 13 | -0.023 | 0.0460 | 0.69 | 0.78 | 0.90 | 12.56 | Nateglinide (Unkonw) Rosiglitazone (Unkonw) Alogliptin (Unkonw) |